1urc: Difference between revisions

No edit summary
No edit summary
 
(20 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Image:1urc.gif|left|200px]]<br />
<applet load="1urc" size="450" color="white" frame="true" align="right" spinBox="true"
caption="1urc, resolution 2.6&Aring;" />
'''CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY'''<br />


==Overview==
==Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly==
Inhibition of cyclin A- and cyclin E-associated cyclin-dependent kinase-2, (CDK2) activities is an effective way of selective induction of apoptotic, cell death via the E2F pathway in tumour cells. The cyclin groove, recognition motif (CRM) in the natural CDK-inhibitory (CDKI) tumour, suppressor protein p27KIP1 was used as the basis for the design and, synthesis of a series of cyclic peptides whose biological activity and, structural characterisation by NMR and X-ray crystallography is reported., Whereas linear p27KIP1 sequence peptides were comparatively ineffective, introduction of side chain-to-tail constraints was found to be productive., An optimal macrocyclic ring size for the conformational constraint was, determined, mimicking the intramolecular H-bonding system of p27., Molecular dynamics calculations of various macrocycles suggested a close, correlation between ring flexibility and biological activity. Truncated, inhibitor peptide analogues also confirmed the hypothesis that, introduction of a cyclic conformational constraint is favourable in terms, of affinity and potency. The structural basis for the potency increase in, cyclic versus linear peptides was demonstrated through the determination, and interpretation of X-ray crystal structures of complexes between, CDK2/cylin A (CDK2A) and a constrained pentapeptide.
<StructureSection load='1urc' size='340' side='right'caption='[[1urc]], [[Resolution|resolution]] 2.60&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[1urc]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1URC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1URC FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.6&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1urc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1urc OCA], [https://pdbe.org/1urc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1urc RCSB], [https://www.ebi.ac.uk/pdbsum/1urc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1urc ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/CDK2_HUMAN CDK2_HUMAN] Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization.<ref>PMID:10499802</ref> <ref>PMID:11051553</ref> <ref>PMID:10995386</ref> <ref>PMID:10995387</ref> <ref>PMID:10884347</ref> <ref>PMID:11113184</ref> <ref>PMID:15800615</ref> <ref>PMID:18372919</ref> <ref>PMID:20147522</ref> <ref>PMID:20079829</ref> <ref>PMID:20935635</ref> <ref>PMID:20195506</ref> <ref>PMID:19966300</ref> <ref>PMID:21262353</ref> <ref>PMID:21596315</ref> <ref>PMID:21319273</ref> <ref>PMID:17495531</ref>
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
Check<jmol>
  <jmolCheckbox>
    <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/ur/1urc_consurf.spt"</scriptWhenChecked>
    <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked>
    <text>to colour the structure by Evolutionary Conservation</text>
  </jmolCheckbox>
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1urc ConSurf].
<div style="clear:both"></div>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Inhibition of cyclin A- and cyclin E-associated cyclin-dependent kinase-2 (CDK2) activities is an effective way of selective induction of apoptotic cell death via the E2F pathway in tumour cells. The cyclin groove recognition motif (CRM) in the natural CDK-inhibitory (CDKI) tumour suppressor protein p27KIP1 was used as the basis for the design and synthesis of a series of cyclic peptides whose biological activity and structural characterisation by NMR and X-ray crystallography is reported. Whereas linear p27KIP1 sequence peptides were comparatively ineffective, introduction of side chain-to-tail constraints was found to be productive. An optimal macrocyclic ring size for the conformational constraint was determined, mimicking the intramolecular H-bonding system of p27. Molecular dynamics calculations of various macrocycles suggested a close correlation between ring flexibility and biological activity. Truncated inhibitor peptide analogues also confirmed the hypothesis that introduction of a cyclic conformational constraint is favourable in terms of affinity and potency. The structural basis for the potency increase in cyclic versus linear peptides was demonstrated through the determination and interpretation of X-ray crystal structures of complexes between CDK2/cylin A (CDK2A) and a constrained pentapeptide.


==About this Structure==
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.,Andrews MJ, McInnes C, Kontopidis G, Innes L, Cowan A, Plater A, Fischer PM Org Biomol Chem. 2004 Oct 7;2(19):2735-41. Epub 2004 Sep 9. PMID:15455144<ref>PMID:15455144</ref>
1URC is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with ACE as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Transferred_entry:_2.7.11.1 Transferred entry: 2.7.11.1], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.37 2.7.1.37] Structure known Active Site: CBG. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1URC OCA].


==Reference==
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes., Andrews MJ, McInnes C, Kontopidis G, Innes L, Cowan A, Plater A, Fischer PM, Org Biomol Chem. 2004 Oct 7;2(19):2735-41. Epub 2004 Sep 9. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=15455144 15455144]
</div>
<div class="pdbe-citations 1urc" style="background-color:#fffaf0;"></div>
 
==See Also==
*[[Cyclin 3D structures|Cyclin 3D structures]]
*[[Cyclin-dependent kinase 3D structures|Cyclin-dependent kinase 3D structures]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Protein complex]]
[[Category: Large Structures]]
[[Category: Transferred entry: 2.7.11.1]]
[[Category: Synthetic construct]]
[[Category: Andrews, M.]]
[[Category: Andrews M]]
[[Category: Cowan, A.]]
[[Category: Cowan A]]
[[Category: Fischer, P.]]
[[Category: Fischer P]]
[[Category: Green, S.]]
[[Category: Green S]]
[[Category: Griffiths, G.]]
[[Category: Griffiths G]]
[[Category: Innes, L.]]
[[Category: Innes L]]
[[Category: Kontopidis, G.]]
[[Category: Kontopidis G]]
[[Category: Lane, D.]]
[[Category: Lane D]]
[[Category: Mcinnes, C.]]
[[Category: McInnes C]]
[[Category: Paterson, D.]]
[[Category: Paterson D]]
[[Category: Plater, A.]]
[[Category: Plater A]]
[[Category: Powers, H.]]
[[Category: Powers H]]
[[Category: Walkinshaw, M.]]
[[Category: Walkinshaw M]]
[[Category: Zheleva, D.]]
[[Category: Zheleva D]]
[[Category: ACE]]
[[Category: cyclin a]]
[[Category: drug design]]
[[Category: inhibitor]]
[[Category: ligand exchange]]
[[Category: peptidomimetics]]
 
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov  5 17:09:36 2007''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA